<DOC>
	<DOCNO>NCT01014650</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics single IV dose GLYX-13 , N-Methyl-D-aspartate ( NMDA ) receptor glycine site functional partial agonist , normal , healthy human volunteer .</brief_summary>
	<brief_title>Single Ascending Dose Safety , Tolerability Pharmacokinetics Study GLYX-13 Normal Volunteers</brief_title>
	<detailed_description>NMDA receptor glycine site partial agonist ( GFPAs ) demonstrate efficacious animal model and/or early human study several Central Nervous System ( CNS ) diseases include neuropathic pain , major depressive disorder , schizophrenia , Alzheimer 's disease , anxiety include posttraumatic stress syndrome , cognition Down 's syndrome autism others , without psychomimetic side effect NMDA receptor channel blocker . GLYX-13 demonstrate wide therapeutic ratio ( 500:1 ) efficacy side effect animal . The purpose study evaluate safety pharmacokinetics GLYX-13 follow single IV dose .</detailed_description>
	<mesh_term>Glycine</mesh_term>
	<criteria>clinical laboratory value &lt; 2x upper limit normal ability understand requirement study provide inform consent alcohol abuse abuse illicit substance current smoker currently take prescription medication ( birth control ) history allergy NMDA receptor ligands receive another investigational drug within 30 day psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>glycine site partial agonist</keyword>
	<keyword>normal volunteer</keyword>
	<keyword>safety normal volunteer</keyword>
</DOC>